ms-colloquium.org
Main scientific programme | The second Pan-European multi-stakeholder colloquium on Multiple Sclerose
http://www.ms-colloquium.org/programme
The second Pan-European multi-stakeholder colloquium on Multiple Sclerose. Day 1 - Friday 15 May 2015. Moderator: Prof. Xavier Montalban (Chair). Welcome and message from Mr. Adam Kosa, member of the European parliament, Co-Chair of the Disability Intergroup. Prof Xavier Montalban (Chair). Outcomes 1st MS multi-stakeholder colloquium. Prof Patrick Vermersch (Co-Chair). The voice of the patient. European MS Platform (EMSP): Our targets. Session 1: Innovation stimulation. Prof Patrick Vermersch (Co-Chair).
ms-colloquium.org
Accreditation | The second Pan-European multi-stakeholder colloquium on Multiple Sclerose
http://www.ms-colloquium.org/programme/accreditation
The second Pan-European multi-stakeholder colloquium on Multiple Sclerose. The second Pan-European MS multi-stakeholder colloquium, stimulating adoption of innovation for better care (Brussels, Belgium, 15. 16.05.2015) was granted. European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). Congress management by Ismar Healthcare. 32 3 491 82 75 info@ms-colloquium.org.
ms-colloquium.org
Privacy policy | The second Pan-European multi-stakeholder colloquium on Multiple Sclerose
http://www.ms-colloquium.org/node/2621
The second Pan-European multi-stakeholder colloquium on Multiple Sclerose. As the colloquium is supported by Teva Pharmaceuticals Europe B.V., its Pharmacovigilance Privacy Policy applies:. Teva Pharmacovigilance Privacy Policy. Definitions used in this Privacy Policy. Means an unwanted, unintended or harmful event in relation to the use of a Teva medicinal product. Means information that relates to any living identifiable individual (e.g. you, your medical practitioner or your family member). We collect...
ms-colloquium.org
Welcome | The second Pan-European multi-stakeholder colloquium on Multiple Sclerose
http://www.ms-colloquium.org/content/welcome-page
The second Pan-European multi-stakeholder colloquium on Multiple Sclerose. Dear Madam, Sir, Colleague,. Due to its early onset, heterogeneous and progressive character, the burden for the patients and the economic impact of multiple sclerosis (MS) are significant and underestimated in comparison with other chronic diseases. There is still no cure for MS and unfortunately, access to ‘and the quality of’ care varies substantially between countries in Europe. 1 How to stimulate innovation? 5 Creating afford...
ms-colloquium.org
Faculty | The second Pan-European multi-stakeholder colloquium on Multiple Sclerose
http://www.ms-colloquium.org/faculty-page
The second Pan-European multi-stakeholder colloquium on Multiple Sclerose. Chair of the Neurology-Neuroimmunology Department and Director of the Multiple Sclerosis Center of Catalonia (CEMCat). Vall d'Hebron University Hospital. Conflict of Interest form. Chair of the Neurology department. University Hospital of Lille, Faculty of Medicine. Conflict of Interest form. Vice Chair of Health Enabling Technology, Office of Clinical Transformation and Director of the Cleveland Clinic Concussion Center. Associat...
ms-colloquium.org
Sponsoring & promotion | The second Pan-European multi-stakeholder colloquium on Multiple Sclerose
http://www.ms-colloquium.org/content/sponsoring-promotion
The second Pan-European multi-stakeholder colloquium on Multiple Sclerose. This meeting is initiated and funded by Teva Pharmaceuticals Europe. The faculty has sole responsibility for the scientific content of the programme and selection of speakers. Teva has had no input into the programme/speaker selection. If you are interested to support or promote this colloquium, please contact us at. You can find promotional material here:. Congress management by Ismar Healthcare.
ms-colloquium.org
Welcome | The second Pan-European multi-stakeholder colloquium on Multiple Sclerose
http://www.ms-colloquium.org/node/2113
The second Pan-European multi-stakeholder colloquium on Multiple Sclerose. Dear Madam, Sir, Colleague,. Due to its early onset, heterogeneous and progressive character, the burden for the patients and the economic impact of multiple sclerosis (MS) are significant and underestimated in comparison with other chronic diseases. There is still no cure for MS and unfortunately, access to ‘and the quality of’ care varies substantially between countries in Europe. 1 How to stimulate innovation? 5 Creating afford...